HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Volume 20, No. 6, June 2016 – Medical Devices & Healthcare Technology       » Seizing Opportunity in Asia-Pacific's Complex and Rapidly Changing Medical Device Market       » IoT in Healthcare       » High Performance Computing Cluster (HPC), Pearcey, a Result of CSIRO-Dell Partnership       » SONY Expanding Footprint in Medical Field       » Biosensors Announces Strategic Agreement with Cardinal Health       » Gene Decides How Young We Look      
EYE ON CHINA
Miraculins to Negotiate Licensing Rights for Diabetes Test in China

Miraculins, a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs has executed of a non-binding Letter of Intent (the “LOI”) with Cachet Pharmaceutical Co. Ltd. (“Cachet”), a 4Billion RMB market cap ($654 Million USD) wholesale/retail drug distribution and medical device distributor, with over 2.5 Billion RMB ($408 Million USD) in annual sales. Cachet is majority state-owned and listed on the Shenzhen Stock Exchange (stock name: Cachet; stock code: 002462). The LOI provides Cachet with a non-exclusive ninety-day negotiation period to acquire an exclusive license to commercialize the Company’s SCOUT DS® Non-Invasive Diabetes Screening Test in Mainland China, towards addressing the devastating growth of that country’s diabetes epidemic and the corresponding economic impact to its healthcare system. There are already 114 million people in China with diabetes.

The goal of the negotiation period is to engage in earnest and accelerated discussions regarding the establishment and execution of a definitive licensing agreement, which would be subject to satisfactory due diligence and board approval by both parties respectively. Under the terms of the LOI, the parties have acknowledged the general terms that could form part of a formalized agreement should they reach that stage in their negotiations, which will abide by Chinese regulations governing Chinese public companies and reflect anticipated market demand within China. The agreement could include Cachet providing to Miraculins an upfront payment, on-going royalties, funding for regulatory approval, and a commitment to conduct and fund market development activities. Miraculins would be responsible for the manufacture and delivery of SCOUT DS® systems toCachet for distribution in China and would provide consultation and support for all related business activities.

A 90 day period of negotiation will be taking place.

Click here for the complete issue.

NEWS CRUNCH  
news Gather China & World Pharmaceutical Entrepreneurs, Create a New Chapter of Chinese Pharma Industry
news Mundipharma's New Betadine® Facility to Meet Regional Healthcare Challenges
news STRATASYS launches World's First Full-ColoUr Multi-material 3D PRINTER - THE J750 - In Singapore
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Healthcare Technology Outlook 2020 - Technology uptake
COLUMNS  
APBN Editorial Calendar 2016
January:
Guest Editorial - Biotechnology In Korea
February:
Guest Editorial - Biomedical Research Governance
March:
Guest Editorial - Life-Saving Opportunities: A Guide to Regenerative Medicine
April:
Leading-Edge ONCOLOGY
May:
Healthcare Systems & Policies in Asia
June:
Medical Devices & Healthcare Technology
July:
Water Technology and Management
August:
Novel Technologies for Antibody Drug Discovery in Japan
September:
Infectious Diseases
October:
Medical Tourism
November:
Biomedical Imaging Technology
December:
Food Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com or Mr Edward
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy